| Abstract | The therapeutic activity of 5-FU in large bowel cancer is enhanced by increasing the intracellular pool of reduced folates. We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days. None had been given previous radio- or chemotherapy. All had measurable disease. Not one complete response was observed. Thirteen of the 39 evaluable patients showed partial response. Median duration of response was 9+ months. The probability of 50% survival was 15 months for all evaluable patients. There was no case of severe toxicity and the principal toxic effects were oral mucositis and diarrhea. To date, HDFA + 5-FU is one of the most effective treatments for large bowel cancer. |
| Authors | C Barone, A Astone, C Garufi, A Grieco, A Cavallaro, G Netri, S Rossi, A Cassano, E Ricevuto, M R Noviello
(Affiliation: Istituto di Clinica Medica, Università Cattolica del Sacro, Roma, Italy.)
|
| Journal | European journal of cancer & clinical oncology
(Eur J Cancer Clin Oncol)
Vol. 23
Issue 9
Pg. 1303-6
(Sep 1987)
ISSN: 0277-5379 ENGLAND |
| PMID | 3500048
(Publication Type: Journal Article)
|
| Chemical References |
|
| Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Colonic Neoplasms
(drug therapy, mortality)
- Diarrhea
(chemically induced)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Humans
- Leucovorin
(administration & dosage, adverse effects)
- Liver Neoplasms
(secondary)
- Male
- Middle Aged
- Mouth Mucosa
- Rectal Neoplasms
(drug therapy, mortality)
- Stomatitis
(chemically induced)
|
